AC Immune to Present at the AD/PD™ 2022 New Clinical and Preclinical Data for Alpha-Synuclein, Abeta and TDP-43 Programs
Five presentations at the International Conference on Alzheimer’s & Parkinson’s Diseases (AD/PDTM)
AC Immune’s Chief Medical Officer to participate in expert forum on translational drug discovery for a-synucleinopathies
AC Immune SA, a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, today announced that five new data presentations will be delivered at the International Conference on Alzheimer’s & Parkinson’s Diseases (AD/PDTM), taking place in Barcelona, Spain, and virtually on March 15–20, 2022. In addition, Prof. Johannes Streffer, Chief Medical Officer of AC Immune SA, will join an expert panel to discuss novel insights, challenges and solutions for innovative approaches in AD and PD therapeutics.